Oncology

A retrospective analysis finds that patients who undergo pneumonectomy or are aged 70 years or older after receiving neoadjuvant concurrent chemoradiation therapy experience less favorable surgical outcomes. Lung cancer, particularly stage IIIA–N2 non-small cell lung cancer (NSCLC), is one of the leading causes of cancer-related deaths worldwide. The most effective treatment approach for this type...

Neoadjuvant chemoimmunotherapy, whether compared to immunotherapy alone or in combination with apatinib, may lead to increased surgical complexity while maintaining an acceptable incidence of postoperative complications, according to the results of a retrospective study. Lung cancer, specifically non-small cell lung cancer (NSCLC), is the leading cause of cancer-related deaths worldwide, accounting for nearly 85% of...

In a retrospective study, patients without a social support network had a shorter survival rate than those with support. Non-small cell lung cancer (NSCLC) continues to be a significant health issue and is a leading cause of death in many countries. Although there are promising new treatments available for certain types of lung cancer, managing...

A cohort study finds that class-switched B cells could potentially be used as a prognostic marker for non-small cell lung cancer and as a target for future therapeutic strategies. Lung cancer is a major global health concern. Significant progress has been made in treatment, with immunotherapy emerging as a recent breakthrough of great promise. The...

A screening of the differentially expressed genes based on the Gene Expression Omnibus database and further gene enrichment analysis indicates that the tyrosine kinase-binding protein TYROBP is a potential prognostic marker for multiple myeloma. Multiple myeloma is a refractory hematological cancer characterized by the malignant proliferation of plasma cells. The tyrosine kinase-binding protein TYROBP mediates...

Double-hit newly diagnosed multiple myeloma patients with minimal residual disease positivity have a poor prognosis compared to patients with minimal residual disease negativity, according to the results of a recent cohort study. Autologous stem cell transplantation (ASCT) is one of the novel therapeutic approaches that are beneficial for newly diagnosed multiple myeloma (NDMM) patients. The...

A random forest radiomics model achieved satisfactory diagnostic performance, and models based on joint CET1 and T2-weighted imaging demonstrated better performance than single-sequence models in differentiating spinal multiple myeloma from metastases.  Spinal metastases and spinal multiple myeloma have similar radiographic characteristics, making accurate differentiation a necessity for precision therapy.  This retrospective study established and assessed...

A new cohort study reports that soluble B-cell maturation antigen is present in the lacrimal fluid of multiple myeloma patients, with evidence of pinocytosis as the underlying mechanism contributing to the development of keratopathy in these patients. Belantamab is an anti-B-cell maturation antigen (anti-BCMA) antibody–drug conjugate approved for the pharmacological treatment of refractory multiple myeloma....

A retrospective analysis finds high-risk fluorescent in situ hybridization markers useful for stratifying real-world survival outcomes in newly diagnosed multiple myeloma patients. Interphase fluorescent in situ hybridization (iFISH) remains the standard of care for assessing prognosis in patients with newly diagnosed multiple myeloma (NDMM). There is, however, limited data regarding iFISH-based real-world survival outcomes. In...